ENTROPY NEURODYNAMICS LIMITED — Board/Management Information 2024

Jul 29, 2024

ASX Release

30 July 2024

==> picture [210 x 47] intentionally omitted <==

Appointment of Professor Phillipa Hay further strengthens Tryptamine’s Scientific Advisory Board

• Phillipa Hay, MD. a highly regarded Professor and Chair of Mental Health at Western Sydney University, has been appointed to the Tryp Therapeutics Scientific Advisory Board for a three-year term

• Professor Hay is an academic psychiatrist who is recognised internationally for her expertise in reducing the personal and public health burden of eating disorders and obesity. She has over 400 peer reviewed publications, written and co-edited several books, and has won several awards including the 2015 Australian and New Zealand Academy Lifetime Achievement award

• Her current research focus is on evaluations of interventions for anorexia nervosa and other eating disorders, including the application of psychedelic treatments to achieve improved health outcomes, as well as public health and community interventions that will reduce barriers to accessing care programs

• Professor Hay has a DPhil in Psychiatry from the University of Oxford and MD (Medicine) from University of Otago, is a Fellow of the RANZCP, and Fellow of the Academy for Eating Disorders (AED)

  • ---

Melbourne, Australia – Tryptamine Therapeutics Limited (‘ Tryp ’ or the ‘ Company ’) ( ASX: TYP ), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which can be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to announcement the appointment of Professor Phillipa Hay to its Scientific Advisory Board (‘SAB’).

Professor Hay is an academic psychiatrist who is recognised internationally for her research and expertise in improving health outcomes associated with eating disorders and obesity. She has published over 500 Web of Science core collection scientific papers and regularly presents her work nationally and internationally. Her work has been influential in providing evidence-based research to inform clinical practice and establish national and international guidelines for the treatment of eating disorders.

She led the working group for the Royal Australian and New Zealand College of Psychiatrists national guidelines for eating disorder treatments, and also played a central role in establishing the EDP framework for Australians who are experiencing eating disorders to access recovery support through Medicare.

In 2015, Professor Hay received the Lifetime Leadership Award from the ANZ Academy for Eating Disorders, and in 2020 she was awarded the RANZCP Senior Research Award. She is the founding Editor-in-Chief of the first online journal in her research area, Journal of Eating Disorders, and is a past-President of the Australian Academy for Eating Disorders.

Her current research focuses on clinical trials of interventions for anorexia nervosa and other eating disorders, as well as public health and community interventions that will reduce barriers to accessing care. Other studies have explored diagnostics of disordered eating behaviours and eating disorder mental health literacy both the community and the medical profession. Her areas of interest also include the application of psychedelics in eating disorder treatments, where she currently serves as co-editor of submissions for a collection being compiled by the Journal of Eating Disorders titled ‘Mindful Journeys: A Careful Exploration of Psychedelics in Eating Disorder Treatment’.

Professor Hay is a principal reviewer and writer of systematic reviews internationally in the field of eating disorders for the highly regarded Cochrane Library. As a highly regarded commentator, she is regularly invited to submit articles and commentaries to Australasian and International journals, publications and books.

==> picture [210 x 47] intentionally omitted <==

Professor Hay commented: “I am very pleased to join the Strategic Advisory Board and be part of furthering understanding of novel interventions such as the Psychedelics which have potential to enhance psychological therapies and care for people with eating disorders”.

Chief Executive Officer, Mr. Jason Carroll said: “We are thrilled to welcome Professor Hay to the Strategic Advisory Board. Her appointment reflects the ongoing commitment by the Tryp Therapeutics Board and management team to recruit bestin-class practitioners to help guide the strategic direction of the business by providing key insights that leverage their specific area of expertise. This is a core strategy of the business and one which we believe provides Tryp with a unique advantage in pursuit of our stated clinical development pathway. We look forward to working with Professor Hay - one of the world’s foremost authorities on how to achieve improved health outcomes for people suffering from eating disorders – and leveraging her insights to inform the development of our proprietary development suite for the application of psilocin to achieve improved health outcomes.”

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience. TRP-8803 is currently being evaluated in a Phase 1 Healthy Volunteer Study in Adelaide, Australia.

For more information, please visit www.tryptherapeutcs.com.

Investor & Media Contact

Jason Carroll Chief Executive Officer Tryptamine Therapeutics Limited jcarroll@tryptherapeutcs.com

Henry Jordan Six Degrees Investor Relations +61 (0) 431 271 538 henry.jordan@sdir.com.au

==> picture [210 x 47] intentionally omitted <==

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp’s Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.